Pregnancy under high-dose buprenorphine

Characteristics and quality of life of opioid-dependent pregnant women in Austria

“…Concurrent opioid consumption in her sample was lower as well (7.7% and 0.0% versus 47.7% and 30.4% in methadone- and buprenorphine-maintained women, respectively, in the present study). Simmat-Durand et al (2009) reported a higher rate of concomitant benzodiazepine use (22%) and a lower rate of cocaine use (5%) in the four weeks prior to delivery in buprenorphine-maintained patients compared to the current study sample in the last trimester (17.2% benzodiazepine use and 13.6% cocaine use in the buprenorphine group). Dryden et al (2009) reported concomitant benzodiazepine use by 60.4% of pregnant methadone-maintained patients, and cocaine, heroin, and cannabis use by 7.1%, 51.1%, and 18.2% of the patients, respectively.…”

“…Jones et al 2005) and lower buprenorphine doses (e.g. Simmat-Durand et al 2009, Bartu et al 2012), respectively. In regard to average daily SROM doses at time of delivery, no data from other treatment centers are available for comparison.…”

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence

“…About half of the babies born to women treated with methadone or high-dose buprenorphine require treatment for NAS (Simmat-Durand et al 2009). Binder and Vavrinka (2008) reported the results of a randomized, prospective study of 147 intravenous heroin-addicted pregnant women in the Czech Republic.…”

Les effets indésirables des médicaments de substitution dans le traitement de la dépendance aux opioïdes

“…Une étude réalisée en France auprès de 159 femmes recevant de la buprénorphine durant leur grossesse a mis en évidence un taux de sevrage néonatal, suffisamment sévère pour nécessi-ter un traitement, d'environ 50 % (Simmat-Durand, Lejeune & Gourarier, 2008). La durée ou sévérité du sevrage n'était pas reliée à la dose de buprénorphine, mais plutôt à l'observance du traitement.…”